Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Immunotherapy: KEYNOTE-028 trial

Esmo 5 Immunotherapy- KEYNOTE-028 trial

In this session, the speakers discuss the reasons for failure of immunotherapy in prostate cancer. The speakers also analyze the overall response rate in the KEYNOTE trial with pembrolizumab monotherapy. They refer to interesting observations in this study such as none of the patients died or discontinued pembrolizumab due to treatment-related adverse events and the demonstration of anti-tumour activity and favourable safety profile.

Next video

  • Imaging

    In this session, the speakers discuss the uses and clinical trials of Radium 223 therapy . They discuss the key...

Additional materials

  • Additional resources

    Abstract 725PD: Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

    Hansen et al.

    Annals of Oncology 27 (Supplement 6): vi243-vi265, 2016

    Link to full-article: http://annonc.oxfordjournals.org/content/27/suppl_6/725PD.full.pdf


    725PD: Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

    [Awaiting permission for poster]